compound 18

structure

Also Known As:

N-(3-acetamido-5-N-methylacetamido-2,4,6-triiodobenzoyl)-2-amino-2-deoxy-D-glucitol; D-Glucitol, 2-((3-(acetylamino)-5-(acetylmethylamino)-2,4,6-triiodobenzoyl)amino)-2-deoxy-

Networked: 86 relevant articles (6 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzoates: 426
        Iodobenzoates
        Triiodobenzoic Acids: 2
        compound 18: 86
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Benzoates: 426
      - Iodobenzoates
        Triiodobenzoic Acids: 2
        compound 18: 86

Experts

1.	Jois, Seetharama D: 3 articles (01/2020 - 09/2017)
2.	Tao, Weikang: 2 articles (07/2022 - 02/2021)
3.	Zhang, Lei: 2 articles (06/2022 - 02/2021)
4.	Czopek, Anna: 2 articles (08/2020 - 01/2019)
5.	Zagórska, Agnieszka: 2 articles (08/2020 - 01/2019)
6.	Briere, Daniel A: 2 articles (07/2020 - 01/2015)
7.	Sałat, Kinga: 2 articles (01/2019 - 01/2012)
8.	Pallerla, Sandeep: 2 articles (02/2018 - 09/2017)
9.	Sable, Rushikesh: 2 articles (02/2018 - 09/2017)
10.	Singh, Sitanshu: 2 articles (02/2018 - 09/2017)

Related Diseases

1.	Body Weight (Weight, Body) 07/17/2020 - "Cumulative food intake, body weight, and adiposity do not differ between Tgr5Hep+/+ and Tgr5Hep-/- mice with or without treatment with Compound 18. " 01/10/2013 - "From these studies compound 18 proved to be useful, which at low oral dose of 1 (mg/kg)/day body weight increased bone mass density and volume, expression of osteogenic genes (RUNX2, BMP-2, and ColI), bone formation rate (BFR), and mineral apposition rate (MAR), improved the trabecular microarchitecture, and decreased bone turn over markers in an ovariectomized rodent model for postmenopausal osteoporosis." 06/17/2022 - "The in vivo antitumor evaluation suggested that compound 18 significantly decreased the average tumor volume and tumor weight without any effect on body weight, which is better than 5-Fu. "
2.	Postmenopausal Osteoporosis 01/10/2013 - "From these studies compound 18 proved to be useful, which at low oral dose of 1 (mg/kg)/day body weight increased bone mass density and volume, expression of osteogenic genes (RUNX2, BMP-2, and ColI), bone formation rate (BFR), and mineral apposition rate (MAR), improved the trabecular microarchitecture, and decreased bone turn over markers in an ovariectomized rodent model for postmenopausal osteoporosis."
3.	Colonic Neoplasms (Colon Cancer) 11/23/2016 - "Compound 18 selectively inhibited LRS-mediated mTORC1 activation and exerted specific cytotoxicity against colon cancer cells with a hyperactive mTORC1, suggesting that 18 may offer a novel treatment option for human colorectal cancer." 04/01/2005 - "The prominent compound 18 showed significant activity against cell lines of colon cancer (HCT-116), renal cancer (786-0) and melanoma (M14) (GI50 in the range 0.33-1.08 microM) as well as good selectivity toward non-small cell lung cancer (HOP-62) cells (GI50 = 0.05 microM, TGI = 0.38 microM and LC50 = 4.83 microM)." 09/30/2018 - "OA bearing a α-d-mannose moiety at C28 (compound 18) focused our interest because the estimated inhibitory concentration 50 was similar to that reported for ginsenoside Rh2 against colon cancer cells and it inhibits the G1-S phase transition affecting the cell viability and apoptosis. "
4.	Chronic Pain 01/01/2019 - "Compound 18 also demonstrated a broader spectrum of anticonvulsant activity than phenytoin and showed statistically significant antinociceptive properties in selected models of chronic pain."
5.	Hyperphosphatemia 10/01/2022 - "Our findings suggest that combination therapy with lanthanum carbonate and compound 18 will not only provide better treatment outcomes for hyperphosphatemia but also reduce gastrointestinal side effects in patients." 10/01/2022 - "Oral administration of compound 18 in rats showed a reduction in phosphate absorption comparable to that observed with lanthanum carbonate, a clinically effective phosphate binder used in hyperphosphatemia treatment. "

Related Drugs and Biologics

1.	Minerals
2.	Antigens
3.	Phosphates (Orthophosphate)
4.	Phenytoin (Dilantin)
5.	Isoproterenol (Isoprenaline)
6.	Emetics
7.	Anticonvulsants (Antiepileptic Drugs)
8.	Mechanistic Target of Rapamycin Complex 1
9.	lanthanum carbonate (Fosrenol)
10.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Oral Administration
2.	Therapeutics
3.	Immunotherapy
4.	Castration